Immune modulation underpins the anti‐cancer activity of HDAC inhibitors

Aberrant protein acetylation is strongly linked to tumorigenesis, and modulating acetylation through targeting histone deacetylase (HDAC) with small‐molecule inhibitors has been the focus of clinical trials. However, clinical success on solid tumours, such as colorectal cancer (CRC), has been limite...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wiktoria Blaszczak, Geng Liu, Hong Zhu, Wojciech Barczak, Amit Shrestha, Gulsah Albayrak, Shunsheng Zheng, David Kerr, Anastasia Samsonova, Nicholas B. La Thangue
Formato: article
Lenguaje:EN
Publicado: Wiley 2021
Materias:
Acceso en línea:https://doaj.org/article/44339e57e4864182884b12445438ede8
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:44339e57e4864182884b12445438ede8
record_format dspace
spelling oai:doaj.org-article:44339e57e4864182884b12445438ede82021-12-02T10:31:06ZImmune modulation underpins the anti‐cancer activity of HDAC inhibitors1878-02611574-789110.1002/1878-0261.12953https://doaj.org/article/44339e57e4864182884b12445438ede82021-12-01T00:00:00Zhttps://doi.org/10.1002/1878-0261.12953https://doaj.org/toc/1574-7891https://doaj.org/toc/1878-0261Aberrant protein acetylation is strongly linked to tumorigenesis, and modulating acetylation through targeting histone deacetylase (HDAC) with small‐molecule inhibitors has been the focus of clinical trials. However, clinical success on solid tumours, such as colorectal cancer (CRC), has been limited, in part because the cancer‐relevant mechanisms through which HDAC inhibitors act remain largely unknown. Here, we have explored, at the genome‐wide expression level, the effects of a novel HDAC inhibitor CXD101. In human CRC cell lines, a diverse set of differentially expressed genes were up‐ and downregulated upon CXD101 treatment. Functional profiling of the expression data highlighted immune‐relevant concepts related to antigen processing and natural killer cell‐mediated cytotoxicity. Similar profiles were apparent when gene expression was investigated in murine colon26 CRC cells treated with CXD101. Significantly, these changes were also apparent in syngeneic colon26 tumours growing in vivo. The ability of CXD101 to affect immune‐relevant gene expression coincided with changes in the tumour microenvironment (TME), especially in the subgroups of CD4 and CD8 tumour‐infiltrating T lymphocytes. The altered TME reflected enhanced antitumour activity when CXD101 was combined with immune checkpoint inhibitors (ICIs), such as anti‐PD‐1 and anti‐CTLA4. The ability of CXD101 to reinstate immune‐relevant gene expression in the TME and act together with ICIs provides a powerful rationale for exploring the combination therapy in human cancers.Wiktoria BlaszczakGeng LiuHong ZhuWojciech BarczakAmit ShresthaGulsah AlbayrakShunsheng ZhengDavid KerrAnastasia SamsonovaNicholas B. La ThangueWileyarticlecheckpoints inhibitorsHDAC inhibitorsimmunotherapytumour microenvironmentNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENMolecular Oncology, Vol 15, Iss 12, Pp 3280-3298 (2021)
institution DOAJ
collection DOAJ
language EN
topic checkpoints inhibitors
HDAC inhibitors
immunotherapy
tumour microenvironment
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
spellingShingle checkpoints inhibitors
HDAC inhibitors
immunotherapy
tumour microenvironment
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Wiktoria Blaszczak
Geng Liu
Hong Zhu
Wojciech Barczak
Amit Shrestha
Gulsah Albayrak
Shunsheng Zheng
David Kerr
Anastasia Samsonova
Nicholas B. La Thangue
Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
description Aberrant protein acetylation is strongly linked to tumorigenesis, and modulating acetylation through targeting histone deacetylase (HDAC) with small‐molecule inhibitors has been the focus of clinical trials. However, clinical success on solid tumours, such as colorectal cancer (CRC), has been limited, in part because the cancer‐relevant mechanisms through which HDAC inhibitors act remain largely unknown. Here, we have explored, at the genome‐wide expression level, the effects of a novel HDAC inhibitor CXD101. In human CRC cell lines, a diverse set of differentially expressed genes were up‐ and downregulated upon CXD101 treatment. Functional profiling of the expression data highlighted immune‐relevant concepts related to antigen processing and natural killer cell‐mediated cytotoxicity. Similar profiles were apparent when gene expression was investigated in murine colon26 CRC cells treated with CXD101. Significantly, these changes were also apparent in syngeneic colon26 tumours growing in vivo. The ability of CXD101 to affect immune‐relevant gene expression coincided with changes in the tumour microenvironment (TME), especially in the subgroups of CD4 and CD8 tumour‐infiltrating T lymphocytes. The altered TME reflected enhanced antitumour activity when CXD101 was combined with immune checkpoint inhibitors (ICIs), such as anti‐PD‐1 and anti‐CTLA4. The ability of CXD101 to reinstate immune‐relevant gene expression in the TME and act together with ICIs provides a powerful rationale for exploring the combination therapy in human cancers.
format article
author Wiktoria Blaszczak
Geng Liu
Hong Zhu
Wojciech Barczak
Amit Shrestha
Gulsah Albayrak
Shunsheng Zheng
David Kerr
Anastasia Samsonova
Nicholas B. La Thangue
author_facet Wiktoria Blaszczak
Geng Liu
Hong Zhu
Wojciech Barczak
Amit Shrestha
Gulsah Albayrak
Shunsheng Zheng
David Kerr
Anastasia Samsonova
Nicholas B. La Thangue
author_sort Wiktoria Blaszczak
title Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
title_short Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
title_full Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
title_fullStr Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
title_full_unstemmed Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
title_sort immune modulation underpins the anti‐cancer activity of hdac inhibitors
publisher Wiley
publishDate 2021
url https://doaj.org/article/44339e57e4864182884b12445438ede8
work_keys_str_mv AT wiktoriablaszczak immunemodulationunderpinstheanticanceractivityofhdacinhibitors
AT gengliu immunemodulationunderpinstheanticanceractivityofhdacinhibitors
AT hongzhu immunemodulationunderpinstheanticanceractivityofhdacinhibitors
AT wojciechbarczak immunemodulationunderpinstheanticanceractivityofhdacinhibitors
AT amitshrestha immunemodulationunderpinstheanticanceractivityofhdacinhibitors
AT gulsahalbayrak immunemodulationunderpinstheanticanceractivityofhdacinhibitors
AT shunshengzheng immunemodulationunderpinstheanticanceractivityofhdacinhibitors
AT davidkerr immunemodulationunderpinstheanticanceractivityofhdacinhibitors
AT anastasiasamsonova immunemodulationunderpinstheanticanceractivityofhdacinhibitors
AT nicholasblathangue immunemodulationunderpinstheanticanceractivityofhdacinhibitors
_version_ 1718397106863996928